Multiparametric MRI and other imaging methods suitable to stage prostate carcinoma
DOI:
https://doi.org/10.15584/ejcem.2019.4.7Keywords:
Prostate cancer, multiparametric MRI (mpMRI), biparametric MRI (bpMRI), stagingAbstract
Introduction. The role of multiparametric magnetic resonance imaging (mpMRI) in staging prostate carcinoma has been increasing over the last years. It’s high sensitivity is indispensable when diagnosing this disease. It is a very accurate imaging method that helps the physician choose the best treatment method for his patient.
Aim. Assessment of mpMRI which uses both anatomic and functional imaging techniques as a method to diagnose prostatic lesions. Advantages and disadvantages of staging prostate carcinoma with the use of biparametric MRI (bpMRI).
Material and methods. The literature search was performed.
Analysis of the literature. MpMRI can be used in pre-operative staging of prostate cancer. The technique is accurate in diagnosing and assessment of prostate carcinoma with Gleason Score (GS) of 7 and above. It is also recommended when planning a second biopsy of the prostatic gland.
Downloads
References
Ferlay J, Soerjomataram I, Dikshit R, Eser S. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136 (5).
Torre LA, Bray F, Siegel R, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2): 87-108.
Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends-An Update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16-27.
Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol. 2009;6(2):87-95.
Delongchamps NB, Singh A, Haas GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006;13(3):158–168.
Kelloff GJ, Choyke P, Coffey DS. Prostate Cancer Imaging Working Group. Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol. 2009;192(6):1455-1470.
Mottet N, Bellmunt J, Briers E, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Urology. 2017;71(4):618-629.
Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol. 2009;192(6):1471-1480.
Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007;243(1):28-53.
Sangeet Ghai, Masoom A. Haider. Multiparametric-MRI in diagnosis of prostate cancer.
Indian J Urol. 2015;31(3):194–201.
Berman RM, Brown AM, Chang SD, et al. DCE MRI of prostate cancer. Abdom Radiol (NY). 2016;41(5):844-853.
Scialpi M, D’Andrea A, Martorana E, et al. Biparametric MRI of the prostate. Turk J Urol. 2017;43(4):401–409.
Bratan F, Niaf E, Melodelima C. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol, 2013;23(7):2019-2029.
Vache T, Bratan F, Mège-Lechvallier F, eta al. Characterization of prostate lesions as benign or malignant at multiparametric MR imaging: comparison of three scoring systems in patients treated with radical prostatectomy. Radiology. 2014;272:446-455.
Barentsz JO, Weinreb JC, Verma S, et al. Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol. 2016;69:41-49.
Jordan EJ, Fiske C, Zagoria R, Westphalen AC. PI-RADS v2 and ADC values: is there room for improvement? Abdom Radiol (NY). 2018;43(11):3109-3116.
Futterer JJ, Briganti A, De Visschere P, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature
Eur Urol. 2015;68:1045-1053.
Zhang L, Tang M, Chen S, Lei X, Zhang X, Huan Y. A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer. Eur Radiol. 2017;27(12):5204-5214.
Smith CP, Türkbey B. PI-RADS v2: Current standing and future outlook.
Turk J Urol. 2018;44(3):189–194.
Müller S, Lilleaasen G, Sand TE, et al. Poor reproducibility of PIRADS score in two multiparametric MRIs before biopsy in men with elevated PSA. World J Urol. 2018;36(5):687-691.
Muller BG, Fütterer JJ, Gupta RT, et al. The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int. 2014;113(2):218-227.
Wysocki JS, Lepor H. Multi-parametric MRI imaging of the prostate-implications for focal therapy. Transl Androl Urol. 2017;6(3):453-463.
Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017.
Killock D. Prostate cancer: Improving diagnosis - can MP-MRI fulfil its PROMIS?
Nat Rev Clin Oncol. 2017;14(3):137.
Faiena I, Salmasi A, Mendhiratta N, et al. PI-RADSv2 Category on 3 Tesla Multiparametric Prostate MRI Predicts Oncologic Outcomes in Gleason 3+4 Prostate Cancer on Biopsy. J Urol. 2018;21.
Sherrer RL, Glaser ZA, Gordetsky JB, Nix JW, Porter KK, Rais-Bahrami S. Comparison of biparametric MRI to full multiparametric MRI for detection of clinically significant prostate cancer. Prostate Cancer Prostatic Dis. 2018;9.
Kuhl CK, Bruhn R, Krämer N, Nebelung S, Heidenreich A, Schrading S. Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen.
Radiology. 2017;285(2):493-505.
Di Campli E, Delli Pizzi A, Seccia B, et al. Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: Comparison between readers with different experience. J Radiol. 2018;101:17-23.
Outwater EK, Montilla-Soler JL. Imaging of prostate carcinoma. Cancer Control. 2013;20(3):161-176.
Schuster DM, Nanni C, Fanti S. Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs. J Nucl Med. 2016;57(3):61-66.
Langsteger W, Rezaee A, Pirich C, Beheshti M. 18F-NaF-PET/CT and 99mTc-MDP Bone Scintigraphy in the Detection of Bone Metastases in Prostate Cancer. Semin Nucl Med. 2016;46(6):491-501.
Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
J Nucl Med. 2006;47(2):287-97.
Wallitt KL, Khan SR, Dubash S, Tam HH, Khan S, Barwick TD. Clinical PET Imaging in Prostate Cancer. Radiographics. 2017;37(5):1512-1536.
Parent EE, Schuster DM. Update on 18F-Fluciclovine PET for Prostate Cancer Imaging. J Nucl Med. 2018;59(5):733-739.
Schuster DM, Nanni C, Fanti S. PET Tracers Beyond FDG in Prostate Cancer. Semin Nucl Med. 2016;46(6):507-521.
Yu J, Fulcher AS, Turner MA, Cockrell CH, Cote EP, Wallace TJ. Prostate cancer and its mimics at multiparametric prostate MRI. Br J Radiol. 2014;87(1037):20130659.
Zhu Y, Wang L, Liu M, Qian C, Yousuf A, Oto A, Shen D. MRI-based prostate cancer detection with high-level representation and hierarchical classification. Med Phys. 2017;44(3):1028-1039.
Thomas S, Oto A. Multiparametric MR imaging of the Prostate: Pitfalls in Interpretation. Radiol Clin North Am. 2018;56(2):277-287.
Bockholt N, Marks LS.Targeted prostate biopsy using magnetic resonance imaging-ultrasound fusion. Asian J Androl. 2015;17(6):870-3.
Lista F, Castillo E, Gimbernat H, Rodríguez-Barbero JM, Panizo J, Angulo JC. Multiparametric magnetic resonance imaging predicts the presence of prostate cancer in patients with negative prostate biopsy. Actas Urol Esp. 2015;39(2):85-91.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
